Aeglea BioTherapeutics Garners $44,000,000 Series B Round

  • Feed Type
  • Date
    3/23/2015
  • Company Name
    Aeglea BioTherapeutics
  • Mailing Address
    901 S. MoPac Expressway Austin, TX 78746 USA
  • Company Description
    Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
  • Website
    http://www.aegleabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $44,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds from the financing will be used to support the continued development of Aeglea’s innovative pipeline of engineered human enzymes that target diseases at the extremes of abnormal metabolism.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy